Diflunisal therapy for cardiac ATTR amyloidosis: a longitudinal, prospective, single centre study

نویسندگان

  • Candida C Quarta
  • Sevda Ozer
  • Carol J Whelan
  • Marianna Fontana
  • Dorota M Rowczenio
  • Janet A Gilbertson
  • Philip N Hawkins
  • Julian D Gillmore
چکیده

Background The transthyretin (TTR) stabilizer diflunisal has been shown to reduce the rate of progression of neurological manifestations in patients with hereditary ATTR amyloidosis. However, data on the effect of diflunisal on cardiac structure and function in amyloidotic hearts are lacking. We report the echocardiographic profiles and cardiac biomarkers of patients with either mutant (M) or wild-type (WT) TTR-related cardiac amyloidosis (ATTR-CA) who received treatment with diflunisal compared to matched untreated patients.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.

BACKGROUND Differentiating immunoglobulin light-chain (AL) from transthyretin-related cardiac amyloidoses (ATTR) is imperative given implications for prognosis, therapy, and genetic counseling. We validated the discriminatory ability of (99m)Tc-pyrophosphate ((99m)Tc-PYP) scintigraphy in AL versus ATTR. METHODS AND RESULTS Forty-five subjects (12 AL, 16 ATTR wild type, and 17 ATTR mutants) un...

متن کامل

Tc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis from the Transthyretin-related Familial and Senile Cardiac Amyloidoses

Background—Differentiating immunoglobulin light-chain (AL) from transthyretin-related cardiac amyloidoses (ATTR) is imperative given implications for prognosis, therapy, and genetic counseling. We validated the discriminatory ability of Tc-pyrophosphate scintigraphy (TcPYP) in AL vs. TTR-related cardiac amyloidoses. Methods and Results—45 subjects (12 AL, 16 ATTR wild-type, and 17 ATTR mutants)...

متن کامل

Successful Diflunisal Desensitization in a Transthyretin Amyloidosis Patient with NSAID Allergy: A Case Report

Introduction: Amyloid diseases have been known to be hereditary, including transthyretin (TTR) amyloidosis where subunit protein mutations may occur in genes for TTR leading to the deposition of fibrils (low molecular weight subunits (5 to 25 kD) of proteins) in extracellular tissues. By reducing the formation of TTR amyloid, diflunisal, a nonsteroidal anti-inflammatory drug (NSAID), has shown ...

متن کامل

The landscape of treatment of chronic kidney disease in hereditary ATTR amyloidosis

Hereditary transthyretin amyloidosis (ATTR) is an autosomal dominant disease, caused by mutations in the TTR gene, the most prevalent being V30M. Although each TTR variant has a different involvement, peripheral neuropathy and cardiomyopathy are predominant. Kidney deposits are well recognized since the original description of the disease as well as a renal phenotype is also likely. Kidney invo...

متن کامل

Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy

Hereditary transthyretin (ATTR) amyloidosis is a debilitating highly penetrant autosomal dominant disease leading to motor disability within 5 years and generally fatal within a decade without treatment. In Italy, hereditary ATTR amyloidosis shows broad genetic and phenotypic variability. Peripheral nerve damage can be isolated, in the absence of cardiac and autonomic involvement. Such a presen...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 10  شماره 

صفحات  -

تاریخ انتشار 2015